JHLT: The Podcast

In this episode, JHLT: The Podcast continues the Pulmonary Hypertension theme for the month, exploring the study "Long-Term outcomes of stent-based pulmonary angioplasty for isolated peripheral pulmonary artery stenosis," which appears in the September print issue of JHLT.
Today's guest is author Hiroto Shimokawahara, MD, of the Okayama Medical Center in Japan.
Dr. Shimokawahara's discussion with Digital Media Editor Van-Khue Ton covers:
What the study contributes to the clinical literature with longer-term outcomes of stent-based pulmonary angioplasty in peripheral pulmonary artery stenosis (PPAS)
How the diffuse nature of PPAS and the advanced stage of disease complicates treatment options
The evolution of stent choices and technologies in the last 20 years of clinical practice at their center
Ideal follow-up conditions for monitoring patients after PPAS stenting
For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.
Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

Today, JHLT: The Podcast discusses "Long-term effects of medical therapy pre- and post-pulmonary endarterectomy—insights from the UK CURATE registry," a manuscript available online now and in the September print issue of JHLT.
Today's guest is first author Paula Appenzeller, MD, of the National Pulmonary Vascular Diseases Unit at Royal Papworth Hospital in Cambridge.
In the episode, Dr. Appenzeller and the editors discuss:
How findings from the UK CURATE registry challenge assumptions about pre-operative therapy in CTEPH
What's important about the 6-minute walk distance test
How hemodynamics help guide post-PEA treatment decisions
If multimodal CTEPH treatment could become the norm
For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.
Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

In this episode, JHLT: The Podcast explores the study "The ASSIST CLAD study: A phase 2 randomized controlled trial of mesenchymal stromal cells for new-onset chronic lung allograft dysfunction," which appears in the August print issue of JHLT.
Today's guest is Daniel C. Chambers, MBBS, MD, of The Prince Charles Hospital and Queensland Lung Transplant Service in Brisbane, Australia.
From across the dateline, he and Digital Media Editor Erika Lease discuss:
What inspired the team to explore the use of mesenchymal stromal cell (MSC) infusions in CLAD patients
Preparation and treatment considerations for using MSCs
How despite the negative outcome—the MSCs made no clear improvements in the patient groups—the study still pushes the field forward
For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.
Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

Today, JHLT: The Podcast discusses "Improved outcomes and donor utilization in heart transplantation with 10 °C static cold storage," a manuscript available online now and in the August print issue of JHLT.
Today's guest is senior author John Trahanas, MD, of the Vanderbilt University School of Medicine in Nashville, TN USA.
In the episode, Dr. Trahanas and the editors discuss:
What was learned from the lung 10°C trials and how the team adapted the devices for hearts
The improved outcomes in PGD and survivability observed in the 10°C group
How to determine if switching from ice to 10°C actually changed donor selection practices—and how it enabled the team to use more hearts
For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.
Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

In case you missed it, JHLT: The Podcast is re-releasing a past audience favorite for your listening pleasure. This month, we revisit a conversation regarding a study from the April 2025 issue of JHLT about the efficacy and safety of sotatercept in patients with PAH.
This conversation with Ioana Preston, MD, of the Tufts University School of Medicine in Boston, explores:
What makes sotatercept unique as the first "biologic" in the treatment of PAH
Hypotheses about the mechanism of action in sotatercept
Sotatercept's interaction with mPAP and what it indicates about the drug's action on the pulmonary vasculature
For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.
Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.